Prevalence of Anemia and Associated Factors among Newly Diagnosed Patients with Solid Malignancy at Tikur Anbessa Specialized Hospital, Radiotherapy Center, Addis Ababa, Ethiopia.
Journal
Advances in hematology
ISSN: 1687-9104
Titre abrégé: Adv Hematol
Pays: United States
ID NLM: 101504271
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
04
2019
revised:
13
07
2019
accepted:
31
07
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
30
11
2019
Statut:
epublish
Résumé
Anemia is a common finding in cancer, which is caused by many factors. It is a major cause of morbidity in cancer patients, worsens disease status and impairs treatment outcome; however, little is known about the prevalence of anemia and associated factors among cancer patients during diagnosis in developing countries like Ethiopia. In response to this, we have conducted research with the aim of assessing the prevalence of anemia and associated factors among newly diagnosed patients with solid malignancy at Tikur Anbessa Specialized Hospital (TASH), Radiotherapy center, Addis Ababa, Ethiopia. Descriptive cross-sectional study was conducted from April to May 2014. A total of 422 newly diagnosed patients with solid malignancy attending Radiotherapy center, TASH were enrolled to assess anemia prevalence and associated factors. Data were coded, entered and analyzed using SPSS version16. Using logistic regression, chi squares, Odds ratio and 95% confidence intervals were computed to measure strength of association between variables. Out of 422 respondents, 285 (68%) were females and 153 (36%) of respondents fell into 35-49 age group with age range between 18 and 80 years and the median age of 45. Magnitude of solid cancers was gynecologic (28.9%), breast (22.7%), nasopharyngeal carcinoma (NPC) (7.6%), colorectal (7.1%), sarcoma (6.9%), head and neck (4.5%), thyroid (3.3%), hepatoma (1.9%), and others (17.1%). The overall prevalence of anemia across different tumor was 23% and higher anemia prevalence was noted in gynecologic (37.7%) and colorectal carcinomas (26.7%). The majority of the anemic patients (68%) remained untreated for anemia. The mean trigger hemoglobin for transfusion was 7.7 g/dl. About 83.5% of anemia was mild to moderate type. Performance status (AOR = 3.344; 95% CI 1.410-7.927) and bleeding history (AOR = 3.628; 95% CI 1.800-7.314) showed statistically significant association with occurrence of anemia with Among solid cancers, gynecologic cancer remained the dominant one. Anemia prevalence was 23% in general, in which gynecologic and colorectal cancers were more prevalent. ECOG performance status and bleeding history showed a statistically significant association with the occurrence of anemia.
Sections du résumé
BACKGROUND
BACKGROUND
Anemia is a common finding in cancer, which is caused by many factors. It is a major cause of morbidity in cancer patients, worsens disease status and impairs treatment outcome; however, little is known about the prevalence of anemia and associated factors among cancer patients during diagnosis in developing countries like Ethiopia. In response to this, we have conducted research with the aim of assessing the prevalence of anemia and associated factors among newly diagnosed patients with solid malignancy at Tikur Anbessa Specialized Hospital (TASH), Radiotherapy center, Addis Ababa, Ethiopia.
METHODS
METHODS
Descriptive cross-sectional study was conducted from April to May 2014. A total of 422 newly diagnosed patients with solid malignancy attending Radiotherapy center, TASH were enrolled to assess anemia prevalence and associated factors. Data were coded, entered and analyzed using SPSS version16. Using logistic regression, chi squares, Odds ratio and 95% confidence intervals were computed to measure strength of association between variables.
RESULT
RESULTS
Out of 422 respondents, 285 (68%) were females and 153 (36%) of respondents fell into 35-49 age group with age range between 18 and 80 years and the median age of 45. Magnitude of solid cancers was gynecologic (28.9%), breast (22.7%), nasopharyngeal carcinoma (NPC) (7.6%), colorectal (7.1%), sarcoma (6.9%), head and neck (4.5%), thyroid (3.3%), hepatoma (1.9%), and others (17.1%). The overall prevalence of anemia across different tumor was 23% and higher anemia prevalence was noted in gynecologic (37.7%) and colorectal carcinomas (26.7%). The majority of the anemic patients (68%) remained untreated for anemia. The mean trigger hemoglobin for transfusion was 7.7 g/dl. About 83.5% of anemia was mild to moderate type. Performance status (AOR = 3.344; 95% CI 1.410-7.927) and bleeding history (AOR = 3.628; 95% CI 1.800-7.314) showed statistically significant association with occurrence of anemia with
CONCLUSION
CONCLUSIONS
Among solid cancers, gynecologic cancer remained the dominant one. Anemia prevalence was 23% in general, in which gynecologic and colorectal cancers were more prevalent. ECOG performance status and bleeding history showed a statistically significant association with the occurrence of anemia.
Identifiants
pubmed: 31781226
doi: 10.1155/2019/8279789
pmc: PMC6855075
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8279789Informations de copyright
Copyright © 2019 Edosa Kifle et al.
Déclaration de conflit d'intérêts
Authors declare that they have no conflicts of interest.
Références
Adv Hematol. 2019 Oct 20;2019:8279789
pubmed: 31781226
Asian Pac J Cancer Prev. 2010;11(5):1229-33
pubmed: 21198268
BMC Cancer. 2013 Jul 10;13:340
pubmed: 23841898
Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S
pubmed: 15050883
Ann Oncol. 2010 May;21 Suppl 5:v244-7
pubmed: 20555090
Semin Oncol. 2001 Apr;28(2 Suppl 8):54-9
pubmed: 11395854
Asian Pac J Cancer Prev. 2011;12(11):2825-8
pubmed: 22393948
Eur J Cancer. 2004 Oct;40(15):2293-306
pubmed: 15454256
Asian Pac J Cancer Prev. 2012;13(10):5057-61
pubmed: 23244110
Am J Health Syst Pharm. 2007 Feb 1;64(3 Suppl 2):S5-13; quiz S28-30
pubmed: 17244886
Clin Transl Oncol. 2013 Jun;15(6):477-83
pubmed: 23263906
Med J Aust. 2005 May 2;182(9):453-7
pubmed: 15865588
Oncology. 2005;68 Suppl 1:3-11
pubmed: 15855811
Med Oncol. 2008;25(1):12-21
pubmed: 18188710
Ann Oncol. 2012 Aug;23(8):1954-1962
pubmed: 22575608
CMAJ. 2008 Aug 12;179(4):333-7
pubmed: 18695181
Oncologist. 2005 Oct;10(9):743-57
pubmed: 16249356
Cancer Radiother. 2005 Mar;9(2):87-95
pubmed: 15820436
Support Care Cancer. 2012 Jan;20(1):23-8
pubmed: 21107613
Indian J Med Sci. 2008 Oct;62(10):417-20
pubmed: 19008616
Gulf J Oncolog. 2008 Jan;(3):41-5
pubmed: 20084796
J Natl Compr Canc Netw. 2012 May;10(5):628-53
pubmed: 22570293
Ann Oncol. 2010 Oct;21 Suppl 7:vii167-72
pubmed: 20943610